Arrowhead Research Corporation (NASDAQ: ARWR), a
biopharmaceutical company developing targeted RNAi therapeutics,
today announced that the company will make presentations at the
following upcoming events.
The Liver Meeting 2015®, 66th Annual Meeting of
the American Association for the Study of Liver Disease (AASLD)
– San Francisco, November 13-17, 2015
November 15, 3:15 p.m. PST – Christine
Wooddell, Ph.D., Arrowhead group leader will deliver an oral
presentation titled, “Reductions in cccDNA under NUC and ARC-520
therapy in chimpanzees with chronic hepatitis B virus infection
implicate integrated DNA in maintaining circulating HBsAg”
November 16, 8:00 a.m. - 5:30 p.m. PST –
Man-Fung Yuen, M.D., Ph.D., chair of gastroenterology and
hepatology, The University of Hong Kong, and deputy chief of
service, Queen Mary Hospital department of medicine, Hong Kong,
will deliver a late-breaking poster presentation titled,
“ARC-520 produces deep and durable knockdown of viral antigens
and DNA in a phase II study in patients with chronic hepatitis
B”
November 16, 6:30 p.m. PST – Arrowhead
management will host an Analyst and Investor Reception to
discuss ARC-520 and key data being presented at the conference
November 17, 8:00 a.m. - 12:00 p.m. PST –
Christine Wooddell, Ph.D., Arrowhead group leader will deliver a
poster presentation titled, “Monthly dosing of ARC-520 in
chronically hepatitis B virus infected chimpanzees produces rapid,
deep and durable reductions in circulating viral antigens”
Jefferies Autumn 2015 Global Healthcare Conference –
London, UK, November 18-19, 2015
November 19, 2:40 p.m. GMT – Chris Anzalone,
Ph.D., Arrowhead president and chief executive officer, will
present a company overview
Piper Jaffray 27th Annual Healthcare Conference – New
York, December 1-2, 2015
December 2, 3:00 p.m. EST – Chris Anzalone,
Ph.D., Arrowhead president and chief executive officer, will
present a company overview in a fireside chat with Ted Tenthoff,
senior research analyst, Piper Jaffray
HEP DART 2015 – Wailea, Hawaii, December 6-10, 2015
December 2, 6:40 p.m. HST – Bruce Given,
M.D., Arrowhead chief operating officer, will deliver an oral
presentation titled, “New insights on HBV biology from the
ARC-520 development program”
December 8, 4:00 - 5:30 p.m. HST – Christine
Wooddell, Ph.D., Arrowhead group leader will deliver a poster
presentation titled, “Sustained reduction in HBsAg, HBV DNA and
HBeAg seroconversion in a chronically HBV-infected chimpanzee
treated with nucleoside analog/ARC-520 combination therapy”
Links to the webcasts and copies of presentation materials, if
available, can be accessed by visiting the Events section of the
company’s website at
http://ir.arrowheadresearch.com/events.cfm.
About ARC-520
Arrowhead’s RNAi-based candidate ARC-520 is being investigated
in the treatment of chronic HBV infection. The small interfering
RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of
the reverse transcription process where current standard of care
nucleotide and nucleoside analogues act. Arrowhead is investigating
ARC-520 specifically to determine if it can be used to achieve a
functional cure, which is an immune clearant state characterized by
hepatitis B s-antigen negative serum with or without
sero-conversion. Arrowhead is conducting Phase 2b multiple dose and
combination studies in chronic HBV patients. Approximately 350-400
million people worldwide are chronically infected with the
hepatitis B virus, which can lead to cirrhosis of the liver and is
responsible for 80% of primary liver cancers globally.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company
developing targeted RNAi therapeutics. The company is leveraging
its proprietary Dynamic Polyconjugate™ delivery platform to develop
targeted drugs based on the RNA interference mechanism that
efficiently silences disease-causing genes. Arrowhead’s pipeline
includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT
for liver disease associated with alpha-1 antitrypsin deficiency,
ARC-F12 for hereditary angioedema and thromboembolic diseases, and
ARC-HIF2 for renal cell carcinoma.
For more information please visit
http://www.arrowheadresearch.com, or follow us on Twitter
@ArrowRes. To be added to the Company's email list and receive news
directly, please visit
http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our
ability to successfully develop drug candidates, the timing for
starting and completing clinical trials, rapid technological change
in our markets, and the enforcement of our intellectual property
rights. Arrowhead Research Corporation's most recent Annual Report
on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss
some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no
obligation to update or revise forward-looking statements to
reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Research Corporation.
Source: Arrowhead Research Corporation
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151111005352/en/
Arrowhead Research CorporationVince Anzalone,
CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout
GroupChad Rubin646-378-2947ir@arrowres.comorMedia:Russo
PartnersMatt Middleman,
M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Sep 2023 to Sep 2024